Breast Cancer
Research Conducted at Chinese Academy of Medical Sciences Has Provided New Information about Breast Cancer
Published in Women's Health Weekly, April 21st, 2011
2011 APR 21 -- According to recent research published in the journal Cancer Chemotherapy and Pharmacology, "Fulvestrant, an oestrogen receptor (ER) antagonist with no known agonist effects, has shown activity in postmenopausal patients with ER-positive advanced breast cancer recurring or progressing following prior endocrine therapy. This double-blind, double-dummy, randomised phase III study (NCT00327769) was designed to compare the efficacy and safety of fulvestrant versus anastrozole in advanced breast cancer of Chinese postmenopausal women whose disease has progressed following prior endocrine treatment."
"A total of 234 patients were randomised...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
More Articles from Women's Health Weekly
- Endometriosis
Data from Cornell University Provide New Insights into Endometriosis - Ovarian Cancer
Data from K.D. Swenerton and Colleagues Advance Knowledge in Ovarian Cancer - Breast Cancer
Data from M. Weichhaus and Colleagues Advance Knowledge in Breast Cancer - Menopause
Data from Y.S. Yang and Colleagues Advance Knowledge in Menopause - Cervical Cancer
Data on Cervical Cancer Published by Researchers at University of Kentucky - Menopause
Data on Menopause Described by Researchers at University of Copenhagen - More from this issue of Women's Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
